Coripharma

About Coripharma

Based in Hafnarfjörður, Iceland, Coripharma is a European pharmaceutical company operating in the business-to-business market. The firm was established in 2018 through the acquisition of the manufacturing and R&D facilities of Actavis from Teva Pharmaceuticals. This strategic purchase built upon a long history of pharmaceutical production at the site, which originally began in 1981 as Delta hf., later becoming part of Actavis. The company is led by CEO Jonina Gudmundsdottir. This heritage provides Coripharma with a team experienced in the development and manufacturing of generic drugs.

Coripharma's business model is centered on two primary services for other pharmaceutical companies: contract manufacturing and out-licensing. As a contract development and manufacturing organization (CDMO), it specializes in the production of solid oral dosage forms, such as tablets and capsules. Its manufacturing site has an annual production capacity of approximately 1.2 to 1.5 billion units. The company's out-licensing service allows other firms to license Coripharma's own-developed generic products. This offering includes a comprehensive dossier and support services covering the patent landscape, regulatory affairs, and manufacturing, enabling clients to bring products to market under their own brands upon patent expiry. The company's R&D pipeline includes over 30 developed dossiers.

The company's product development focuses on generic pharmaceuticals, with a portfolio of over 20 different generics currently in production. Coripharma's R&D division, staffed by nearly 40 experts, manages the entire product development lifecycle, from selection to the completion of dossiers for regulatory submission. This team leverages decades of experience from their time with predecessors like Actavis and Teva. Significant milestones include the successful pivotal bioequivalence study for Budesonide capsules, used for Crohn's disease, and the development of generic versions of Ponatinib and Binimetinib for treating leukemia and melanoma, respectively. The company has secured significant equity funding from institutional investors, including Icelandic pension funds and the life sciences venture fund Iðunn, to support its growth and R&D activities.